Latest news
Personalised Cancer Vaccines Show Longer-Term Staying Power
Five-year data for intismeran autogene plus pembrolizumab strengthen the case for individualized neoantigen therapy in high-risk resected melanoma.
Ozempic and Eye Health: Balancing Metabolic Benefits with Vision Risks
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
AI Pathology Starts Moving Toward Treatment Selection
Hepatitis B Functional Cure Moves Closer, But Access Still Starts With Diagnosis
Ebola PHEIC Turns Outbreak Control Into a Preparedness Test
Huntington’s Disease Gets an Oral Target-Engagement Signal
A Urine Test for Alzheimer’s Would Change the Access Conversation
AI Multiomics Moves Into the Trial Stratification Layer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.